GTC Consulting
Future-Proof Compliance Excellence

Managing controlled substances demands expert oversight.GTC Consulting stands apart in the DEA compliance space by leading with a proactive, results-oriented approach. Rather than reacting to violations or audits, GTC anticipates regulatory changes, identifies compliance gaps early and implements forward-thinking solutions. This strategy protects clients from enforcement actions, costly fines, and reputational damage.

GTC provides specialized regulatory guidance to pharmaceutical manufacturers, distributors and healthcare entities at the federal and state levels. It serves a diverse client base, from small businesses to Fortune 500 companies, helping them maintain compliance by assisting with DEA registrations and state licenses. It also conducts regulatory audits to identify compliance gaps and help clients stay ahead of evolving requirements.

What truly differentiates GTC is its comfort with complexity. The team embraces high-risk and nontraditional challenges that fall outside the typical scope of DEA consulting, bringing deep regulatory expertise and strategic agility to every engagement.

“Our battle-tested experience goes a long way in helping clients truly understand the totality of the risks,” says Benjamin F. Mink, president and CEO.

A team of seasoned experts, including Ph. D.-level doctors and former DEA leadership, brings deep industry knowledge and strategic insight. It helps clients meet compliance standards and develop proactive strategies to protect their operations.

In today’s high-risk regulatory environment, companies can’t afford guesswork. GTC delivers insight shaped by real regulatory battles and legal proceedings—giving leaders the clarity and confidence to move forward. It’s experts have testified before the U.S. Congress and worked on criminal trials involving executives prosecuted for pharmaceutical distribution violations. This expertise equips it to serve clients with practical, real-world insights to better understand their obligations and effectively mitigate risk.

GTC offers a comprehensive range of DEA compliance and supply chain security services. Beyond controlled substance anti-diversion efforts, preventing the misuse or illegal distribution of regulated medications, it has expanded into security assessments for high-value drugs such as semaglutides ( e.g., Ozempic and Wegovy). These assessments help the team guide clients in developing security strategies, optimizing facility layouts, and implementing biometric scanners, RFID access controls and interlocking doors to prevent theft and diversion.

To help clients succeed during DEA inspections, GTC conducts detailed mock audits that closely follow real DEA evaluation procedures. The goal is to ensure clients are fully prepared, with no surprises. It also assists clients with quality accreditation, including the National Association of Boards of Pharmacy’s (NABP) Drug Distributor Accreditation (DDA), ensuring inventory management and product integrity.

Operating with a deep sense of ownership, GTC treats each project as its own. This commitment fosters trust and long-term partnerships, reinforcing a reputation for delivering effective, client-focused solutions that drive measurable results.

To help manufacturers and distributors evaluate downstream risk, GTC performs detailed Know Your Customer inspections. Client engagement begins with active listening. Every project starts with an in-depth consultation to fully understand a client’s specific challenges and objectives. Creating a customized statement of work ensures that each solution directly addresses the client’s most urgent concerns.

GTC goes beyond traditional DEA compliance support, helping organizations stay aligned with evolving federal regulations. When a leading university began a Schedule I drug research project, progress stalled after its original compliance advisor stepped away. The DEA classifies Schedule I drugs as substances with no accepted medical use and a high potential for abuse. Research involving these drugs requires strict regulatory approval, complex security measures and detailed compliance protocols.

When the project required FDA approval for human clinical trials, GTC secured investigational new drug (IND) approval within 30 days. It also obtained DEA registrations for participating physicians across 20 universities, a feat almost unheard of in the industry.

With a proven track record of navigating complex regulatory landscapes, GTC Consulting is a trusted partner for companies seeking compliant DEA and FDA regulatory solutions. Its proactive and result-oriented approach continues to set the standard in DEA compliance consulting.